{"id":753022,"date":"2023-05-01T08:58:54","date_gmt":"2023-05-01T12:58:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/"},"modified":"2023-05-01T08:58:54","modified_gmt":"2023-05-01T12:58:54","slug":"salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/","title":{"rendered":"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164"},"content":{"rendered":"

\nSubmission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected in second half of 2023
\n<\/h2>\n
\n

HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX)<\/strong>, a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the completion of two Good Laboratory Practice (GLP) toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings during the course of either study. These GLP toxicology reports will be included in the Investigational New Drug (IND) application the company plans to submit to the U.S. Food and Drug Administration (FDA) in the second quarter of 2023.<\/p>\n

\u201cWe are encouraged by the successful completion of these GLP toxicology studies, which represents another significant milestone in the development of SP-3164. Based on preclinical research completed to date, we believe SP-3164 has potential to address several types of lymphomas and other cancers both as monotherapy and in combination with approved standard of care therapies,\u201d said David Arthur, president and chief executive officer of Salarius. \u201cThese results reinforce our belief that SP-3164 holds significant promise to improve the treatment paradigm for blood cancers.\u201d<\/p>\n

Salarius held a pre-IND meeting with the FDA in May 2022 and is in the process of completing activities that will allow it to commence a Phase 1 study in the second half of this year.<\/p>\n

\n About SP-3164<\/strong>
\n
SP-3164 is an oral, next-generation molecular glue that uses Salarius\u2019 deuterium-enabled chiral switching platform to stabilize the preferred (S<\/em>)-enantiomer of avadomide, an extensively studied clinical compound that has demonstrated encouraging single-agent and combination-therapy clinical efficacy in non-Hodgkin Lymphomas (NHL) and other hematologic malignancies. The addition of deuterium at the chiral center of the molecule prevents conversion to the unwanted (R)<\/em>-enantiomer, allowing for isolation and development of the preferred (S<\/em>)-enantiomer into a potential new cancer treatment.<\/p>\n

As such, SP-3164 is a new chemical entity and has been issued a U.S. composition-of-matter patent. Data presented in December 2022 at the American Society for Hematology Annual Meeting showed compelling SP-3164 activity in lymphoma models and supports SP-3164\u2019s potential for the Phase 1 clinical trial in NHL planned to initiate in 2023. Additional supporting data were presented in April 2023 at the American Association for Cancer Research Annual Meeting showing SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and multiple myeloma.<\/p>\n

\n About\u00a0Salarius Pharmaceuticals<\/strong>
\n
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius\u2019 product portfolio includes seclidemstat, Salarius\u2019 lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader. Seclidemstat is currently in a Phase 1\/2 clinical trial for relapsed\/refractory Ewing sarcoma. This trial is currently on a partial clinical hold and is not enrolling new patients. Seclidemstat has received fast track, orphan drug and rare pediatric disease designations for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat\u2019s potential in several cancers with high unmet medical need, with an investigator-initiated Phase 1\/2 clinical study in hematologic cancers at MD Anderson Cancer Center. This trial is currently on a voluntary pause and is not enrolling new patients. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). SP-3164 is currently in IND-enabling studies and anticipated to enter the clinic in 2023. For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.<\/p>\n

\n Forward-Looking Statements <\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as \u201cwill,\u201d \u201cbelieve,\u201d \u201cdeveloping,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cprogress,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201clook forward,\u201d \u201cencouraging,\u201d \u201cmight,\u201d \u201cshould,\u201d and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: the future of the company\u2019s Phase 1\/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas following the recently announced suspected unexpected severe adverse reaction (SUSAR) event and resulting partial clinical hold by the U.S. Food and Drug Administration (FDA); impact that the addition of new clinical sites will have on the development of Salarius\u2019 product candidates; the timing of Salarius\u2019 IND submissions to the FDA and subsequent timing for initiating clinical trials; interim data related to Salarius\u2019 clinical trials, including the timing of when such data is available and made public; Salarius\u2019 growth strategy; the value of seclidemstat as a treatment for Ewing sarcoma, Ewing-related sarcomas, and other cancers and its ability to improve the life of patients; expanding the scope of Salarius\u2019 research and focus to high unmet need patient populations; milestones of Salarius\u2019 current and future clinical trials, including the timing of data readouts. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the FDA may impose additional restrictions on the company\u2019s Phase 1\/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas following the SUSAR, including a partial or full clinical hold; Salarius\u2019 ability to resume enrollment in the clinical trial following its review of the available data surrounding the SUSAR; the sufficiency of Salarius\u2019 capital resources; the ability of, and need for, Salarius to raise additional capital to meet Salarius\u2019 business operational needs and to achieve its business objectives and strategy; future clinical trial results and the impact of such results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; and other risks described in Salarius\u2019 filings with the\u202fSecurities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management\u2019s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.<\/p>\n

\n CONTACT:<\/strong>\n <\/p>\n

LHA Investor Relations
Kim Sutton Golodetz
kgolodetz@lhai.com<\/a>
212-838-3777<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Submission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected in second half of 2023 HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the completion of two Good Laboratory Practice (GLP) toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings during the course of either study. These GLP toxicology reports will be included in the Investigational New Drug (IND) application the company plans to submit to the U.S. Food and Drug Administration (FDA) in the second quarter of 2023. … <\/p>\n

Continue reading “Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753022","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSalarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Submission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected in second half of 2023 HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the completion of two Good Laboratory Practice (GLP) toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings during the course of either study. These GLP toxicology reports will be included in the Investigational New Drug (IND) application the company plans to submit to the U.S. Food and Drug Administration (FDA) in the second quarter of 2023. … Continue reading "Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T12:58:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164\",\"datePublished\":\"2023-05-01T12:58:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/\"},\"wordCount\":1173,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/\",\"name\":\"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=\",\"datePublished\":\"2023-05-01T12:58:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 - Market Newsdesk","og_description":"Submission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected in second half of 2023 HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the completion of two Good Laboratory Practice (GLP) toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings during the course of either study. These GLP toxicology reports will be included in the Investigational New Drug (IND) application the company plans to submit to the U.S. Food and Drug Administration (FDA) in the second quarter of 2023. … Continue reading \"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-01T12:58:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164","datePublished":"2023-05-01T12:58:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/"},"wordCount":1173,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/","name":"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=","datePublished":"2023-05-01T12:58:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODgwNCM1NTY2Mzc4IzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-reports-no-adverse-safety-signals-from-two-good-laboratory-practice-toxicology-studies-with-its-targeted-protein-degrader-sp-3164\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753022"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753022\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}